Afficher la couverture 'The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice | Reber, Laurent, L.' en grand format
/5

0 avis

The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice

Archive ouverte

Reber, Laurent, L. | Starkl, Philipp | Balbino, Bianca | Sibilano, Riccardo | Gaudenzio, Nicolas | Rogalla, Stephan | Sensarn, Steven | Kang, Dongmin | Raghu, Harini | Sokolove, Jeremy | Robinson, William, H | Contag, Christopher, H | Tsai, Mindy | Galli, Stephen, J

Edité par CCSD ; Public Library of Science -

International audience. Gouty arthritis is caused by the deposition of monosodium urate (MSU) crystals in joints. Despite many treatment options for gout, there is a substantial need for alternative treatments for patients unresponsive to current therapies. Tyrosine kinase inhibitors have demonstrated therapeutic benefit in experimental models of antibody-dependent arthritis and in rheumatoid arthritis in humans, but to date, the potential effects of such inhibitors on gouty arthritis has not been evaluated. Here we demonstrate that treatment with the tyrosine kinase inhibitor imatinib mesylate (imatinib) can suppress inflammation induced by injection of MSU crystals into subcutaneous air pouches or into the ankle joint of wild type mice. Moreover, imatinib treatment also largely abolished the lower levels of inflammation which developed in IL-1R1-/- or KitW-sh/W-sh mice, indicating that this drug can inhibit IL-1-independent pathways, as well as mast cell-independent pathways, contributing to pathology in this model. Imatinib treatment not only prevented ankle swelling and synovial inflammation when administered before MSU crystals but also diminished these features when administrated after the injection of MSU crystals, a therapeutic protocol more closely mimicking the clinical situation in which treatment occurs after the development of an acute gout flare. Finally, we also assessed the efficiency of local intra-articular injections of imatinib-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles in this model of acute gout. Treatment with low doses of this long-acting imatinib:PLGA formulation was able to reduce ankle swelling in a therapeutic protocol. Altogether, these results raise the possibility that tyrosine kinase inhibitors might have utility in the treatment of acute gout in humans.

Suggestions

Du même auteur

Pathways of immediate hypothermia and leukocyte infiltration in an adjuvant-free mouse model of anaphylaxis

Archive ouverte | Balbino, Bianca | CCSD

International audience. BACKGROUND:Conflicting results have been obtained regarding the roles of Fc receptors and effector cells in models of active systemic anaphylaxis (ASA). In part, this might reflect the choice...

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Archive ouverte | Gaudenzio, Nicolas | CCSD

International audience. Mast cells (MCs) are hematopoietic cells which reside in various tissues, and are especially abundant at sites exposed to the externalenvironment, such as skin, airways and gastrointestinal t...

Neutrophil myeloperoxidase diminishes the toxic effects and mortality induced by lipopolysaccharide

Archive ouverte | Reber, Laurent, L | CCSD

International audience. Neutrophils have crucial antimicrobial functions but are also thought to contribute to tissue injury upon exposure to bacterial products, such as lipopolysaccharide (LPS). To study the role o...

Chargement des enrichissements...